Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

4round participations

0lead positions

Oct 2025latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

LSLila SciencesScienceLila Sciences (lila.ai) is a privately held AI-for-science company building what it calls an “operating system for…$1.3Bvaluation$985MraisedRecent roundsSeries A (final close / total round close as disclosed) · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) (wholly owned subsidiary), Altitude Life Science Ventures +7Series A (milestone close) · Sep 2025$235M · led by Braidwell, Collective Global +1Lila Sciences$1.3BOct 2025 → Oct 20252 roundsParticipant—

GGenerate:BiomedicinesScienceGenerate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a…$1.1BraisedRecent roundsIPO (initial public offering) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +10Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +8Generate:Biomedicines—Nov 2021 → Sep 20232 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Oct 10, 2025LSLila SciencesScienceLila Sciences (lila.ai) is a privately held AI-for-science company building what it calls an “operating system for…$1.3Bvaluation$985MraisedRecent roundsSeries A (final close / total round close as disclosed) · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) (wholly owned subsidiary), Altitude Life Science Ventures +7Series A (milestone close) · Sep 2025$235M · led by Braidwell, Collective Global +1Lila SciencesSeries A (final close / total round close as disclosed)$350M$1.3BParticipant

Source ↗+1 ↗

Oct 03, 2025LSLila SciencesScienceLila Sciences (lila.ai) is a privately held AI-for-science company building what it calls an “operating system for…$1.3Bvaluation$985MraisedRecent roundsSeries A (final close / total round close as disclosed) · Oct 2025$350M · led by Braidwell, Collective GlobalSeed · Oct 2025$200M · Abu Dhabi Investment Authority (ADIA) (wholly owned subsidiary), Altitude Life Science Ventures +7Series A (milestone close) · Sep 2025$235M · led by Braidwell, Collective Global +1Lila SciencesSeed$200M—Participant

Source ↗

Sep 14, 2023GGenerate:BiomedicinesScienceGenerate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a…$1.1BraisedRecent roundsIPO (initial public offering) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +10Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +8Generate:BiomedicinesSeries C$273M—Participant

Source ↗

Nov 18, 2021GGenerate:BiomedicinesScienceGenerate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a…$1.1BraisedRecent roundsIPO (initial public offering) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +10Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +8Generate:BiomedicinesSeries B$370M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗

Source ↗+1 ↗

Source ↗